eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Phase III randomized study of chimeric antibody 14.18 (CH14.18) in high risk neuroblastoma following myeloablative therapy and autologous stem cell rescue

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
    Chimeric human/murine anti-GD2 monoclonal antibody
  3. Intervention
  4. Resource Description
    "Children eligible for this trial are those with high risk neuroblastoma who have been responding to and are completing chemotherapy, surgery, radiation therapy, and stem cell transplant and have been treated on high risk neuroblastoma protocols. The purpose of this companion study is to compare two different treatments aimed at maintaining or improving patients’ response to high risk treatment. This study involves the use of an investigational agent, ch14.18 (chimeric human/murine anti-GD2 monoclonal antibody). Ch14.18 is a protein made in cultured cells using recombinant DNA technology to humanize antibody made by mice. The chimeric human/murine ch14.18 binds well to neuroblastoma cells and to tumor cells that are positive for GD2, and helps destroy cancer cells. It binds very little to normal tissue. GD2 is a sugar lipid that is strongly expressed on the surface of neuroblastoma cells."
  5. Contact
    Berenberg, Jeffrey
  6. PI
    Wilkinson, Robert, M.D.
  7. Topic
  8. Study Population
    Patients who are between the ages 1-30 years are eligible for this study.
  9. Funded by
    Children's Oncology Group
  10. Phase
    Phase 3 clinical trial
  11. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016